Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

5.385
-0.065-1.19%
Volume:5.44M
Turnover:29.21M
Market Cap:8.59B
PE:-17.11
High:5.545
Open:5.500
Low:5.250
Close:5.450
52wk High:13.150
52wk Low:4.010
Shares:1.60B
HK Float Shares:1.60B
Volume Ratio:0.81
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.315
ROE:-89.13%
ROA:-18.89%
PB:11.95
PE(LYR):-17.11
PS:27.33

Loading ...

CStone Pharmaceuticals' Sugemalimab Receives ESMO Guideline Recommendation for Stage III NSCLC Consolidation Therapy

Stock News
·
Mar 25

CStone Pharmaceuticals’ sugemalimab gains ESMO I,A recommendation; consolidation treatment duration rises to 24 months for stage III NSCLC

Reuters
·
Mar 25

CSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference

Stock News
·
Mar 24

CSTONE PHARMA-B to Present Three Self-Developed Pipeline Findings at Prestigious Global Oncology Conference

Stock News
·
Mar 18

CStone Pharma-B (02616 HK) to Showcase Three Novel ADC Candidates at AACR 2026

Bulletin Express
·
Mar 18

CStone Pharmaceuticals to present preclinical data for three pipeline assets at AACR Annual Meeting

Reuters
·
Mar 18

CStone Pharmaceuticals (SEHK:2616) Valuation Check After New UK Approval For Sugemalimab In Stage III Lung Cancer

Simply Wall St.
·
Mar 09

CSTONE PHARMA-B Shares Surge Over 9% Following FTSE China Inclusion and Progress in Triple Antibody Trial

Stock News
·
Mar 06

CSTONE PHARMA-B Surges Over 12% on Promising Prospects for Major Business Development Deal for its Proprietary Tri-Specific Antibody

Stock News
·
Mar 05

CStone Pharmaceuticals (SEHK:2616) Valuation After New Sugemalimab Indication And US Phase II Trial Clearance

Simply Wall St.
·
Mar 02

CSTONE PHARMA-B Shares Surge Over 8% in Late Trading Following UK Approval for New Lung Cancer Indication

Stock News
·
Feb 27

CStone Pharmaceuticals-B Sees Further Gains Exceeding 6%, Surpassing 25% Monthly Increase

Stock News
·
Feb 25

CStone Pharmaceuticals-B Shares Climb Over 5% Following UK Regulatory Approval for Sugemalimab's New Lung Cancer Indication

Stock News
·
Feb 24

CStone (HKEX: 2616) Gains UK MHRA Approval for Sugemalimab in Stage III NSCLC

Bulletin Express
·
Feb 23

CStone Pharma-B's PD-L1 Antibody Sugemalimab Gains UK Approval for Advanced Lung Cancer

Stock News
·
Feb 23

CStone Pharmaceuticals - Sugemalimab Receives UK Mhra Approval for Stage Iii Nsclc

THOMSON REUTERS
·
Feb 23

UK MHRA approves CStone’s sugemalimab for unresectable stage III NSCLC

Reuters
·
Feb 23